SWK Holdings Corp
Close on Oct 19, 2026
- Market cap
- $303.97M
- P/E (TTM)
- –
- Dividend yield
- 15.92%
About SWK
Miscellaneous Business Credit Institution, SIC 6159
SWK Holdings Corporation is a specialized healthcare capital provider that offers customized financing solutions to life sciences companies, academic institutions, and inventors. Following the sale of its pharmaceutical development assets, the business operates through its finance receivables segment. The company focuses on monetizing cash flows from commercial-stage healthcare products through structured debt, royalty purchases, and synthetic revenue interests. Its clients include biotechnology firms commercializing therapeutics, medical device makers, clinical diagnostic tool developers, and animal health enterprises.
The company maintains its corporate headquarters in Dallas, Texas. SWK Holdings conducts its operations with nine full-time employees. Under its specialty finance strategy, the enterprise and its partners have executed financing transactions with 58 different parties across the life sciences industry. The firm focuses on an underserved market segment by providing capital for transactions valued at under 50 million dollars.
Summary of the business section of SWK's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SWK Holdings Corp
- Founded
- 1996
- Headquarters
- Dallas, TX
- Address
- 5956 Sherry Lane, Suite 650 75225
- Phone
- (214) 217-7253
- Website
- swkhold.com
- Employees
- 9, Dec 31, 2025
- Industry
- Miscellaneous Business Credit Institution
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, San Francisco, CA, USA
Stock & identifiers
- Ticker
- SWKHL
- Exchange
- Nasdaq
- IPO date
- Sep 22, 1999
- Shares outstanding
- 12M, Mar 16, 2026
- Public float
- $45.77M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1089907
- CUSIP
- 78501P203
- ISIN
- US78501P2039
- LEI
- 549300DZ1K2KDX5Q7G55
- EIN
- 77-0435679
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joe David Staggs JR | PRESIDENT | 123,766 |
| Adam Rice | Chief Financial Officer | 15,247 |
| Robert K. Hatcher | Director | 16,662 |
| Laurie L. Dotter | Director | 16,791 |
| Jerry Albright | Director | 10,832 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2023 First Peo | $953.15K | $941.50K | $498.76K | $122 | – |
| FY2022 First Peo | $1.49M | $1.50M | $437.17K | $123 | – |
| FY2022 Second Peo | $1.44M | $1.44M | $437.17K | $123 | – |
| FY2021 Second Peo | $2.38M | $1.75M | $140.00K | $136 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings